Craft

Asensus Surgical

Stock Price

$0.2

2024-06-05

Market Capitalization

$64.2 M

2024-06-04

Revenue

$8.6 M

FY, 2023

Asensus Surgical Summary

Company Summary

Overview
Asensus Surgical (formerlyTransEnterix) is a medical device company developing minimally invasive devices for laparoscopic surgery. It is focused on leveraging robotic technologies, augmented intelligence, and machine learning capabilities to help surgeons during pre-operative, intra-operative, and post-operative phases. The company offers products including Senhance Surgical system, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures. Asensus Surgical also delivers instruments and systems, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue.
Type
Public
Status
Active
Founded
2006
HQ
Durham, NC, US | view all locations
Website
https://asensus.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Wouter Donders

    Wouter Donders, General Manager, EMEA / CIS

    • Anthony Fernando

      Anthony Fernando, President, Chief Executive Officer and Director

    • Wesley Long

      Wesley Long, Vice President of Customer Excellence

    • Amanda Owens

      Amanda Owens, Global Head of People

    Operating MetricsView all

    Patent Applications

    150

    FY, 2021

    Patents (Foreign)

    100

    FY, 2021

    Facility Space Leased (Italy), sq. ft.

    11.7K
    4.1%

    FY, 2021

    LocationsView all

    5 locations detected

    • Durham, NC HQ

      United States

      1 TW Alexander Dr #160

    • Milano, Lombardia

      Italy

      Viale dell’Innovazione 3

    • Tokyo, Tokyo

      Japan

      1-3-5 Kojimachi Chiyoda-ku

    • Bertrange, District de Luxembourg

      Luxembourg

      33 Rue du puits Romain

    • Lugano, TI

      Switzerland

      Via Serafino Balestra 12

    Asensus Surgical Financials

    Summary Financials

    Revenue (Q1, 2024)
    $1.1M
    Gross profit (Q1, 2024)
    ($1.9M)
    Net income (Q1, 2024)
    ($22.5M)
    Cash (Q1, 2024)
    $7.0M
    EBIT (Q1, 2024)
    ($24.6M)
    Enterprise value
    $62.7M

    Footer menu